Literature DB >> 10879639

Comparison of azithromycin and doxycycline in the treatment of erythema migrans.

B Barsic1, T Maretic, L Majerus, J Strugar.   

Abstract

BACKGROUND: A randomized, multicenter, open clinical trial was undertaken in order to compare the efficacies of azithromycin and doxycycline in the treatment of patients with Lyme disease associated with erythema migrans. PATIENTS AND METHODS: A total of 48 patients was treated orally with azithromycin, 500 mg bid on the 1st day, followed by 500 mg once daily for the next 4 days or doxycycline (40 patients) 100 mg bid for 14 days.
RESULTS: Intention-to-treat analysis of clinical efficacy showed no difference between the two treatment regimens. Clinical success was observed in 46 (95.8%) azithromycin- and 33 (82.5%) doxycycline-treated patients, (p = 0.0731). Minor symptoms persisted or appeared in the posttreatment period in two of 47 azithromycin- and three of 35 doxycycline-treated patients (p = 0.646). Major manifestations appeared only in two patients in the doxycycline group (p = 0.179). There was no difference in the tolerability of both drugs.
CONCLUSION: Azithromycin (a total dose of 3 g) is equally effective as standard doxycycline treatment for erythema migrans in adult patients.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10879639     DOI: 10.1007/s150100050069

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  13 in total

Review 1.  Antibiotic treatment of Lyme borreliosis: what is the evidence?

Authors:  R Dinser; M C Jendro; S Schnarr; H Zeidler
Journal:  Ann Rheum Dis       Date:  2005-04       Impact factor: 19.103

Review 2.  Chronic Lyme disease.

Authors:  Paul M Lantos
Journal:  Infect Dis Clin North Am       Date:  2015-06       Impact factor: 5.982

Review 3.  Evidence assessments and guideline recommendations in Lyme disease: the clinical management of known tick bites, erythema migrans rashes and persistent disease.

Authors:  Daniel J Cameron; Lorraine B Johnson; Elizabeth L Maloney
Journal:  Expert Rev Anti Infect Ther       Date:  2014-07-30       Impact factor: 5.091

Review 4.  Management of Lyme Disease in European Children: a Review for Practical Purpose.

Authors:  Matteo D'Alessandro; Anna Loy; Elio Castagnola
Journal:  Curr Infect Dis Rep       Date:  2017-08       Impact factor: 3.725

Review 5.  Persistent Symptoms After Treatment of Lyme Disease.

Authors:  Adriana Marques
Journal:  Infect Dis Clin North Am       Date:  2022-09       Impact factor: 5.905

Review 6.  Chronic Lyme disease: a review.

Authors:  Adriana Marques
Journal:  Infect Dis Clin North Am       Date:  2008-06       Impact factor: 5.982

Review 7.  Efficacy and Safety of Antibiotic Therapy in Early Cutaneous Lyme Borreliosis: A Network Meta-analysis.

Authors:  Gabriel Torbahn; Heidelore Hofmann; Gerta Rücker; Karin Bischoff; Michael H Freitag; Rick Dersch; Volker Fingerle; Edith Motschall; Joerg J Meerpohl; Christine Schmucker
Journal:  JAMA Dermatol       Date:  2018-11-01       Impact factor: 10.282

8.  Genetic Background Amplifies the Effect of Immunodeficiency in Antibiotic Efficacy Against Borrelia burgdorferi.

Authors:  Bijaya Sharma; Julie E McCarthy; Cecily A Freliech; Morgen M Clark; Linden T Hu
Journal:  J Infect Dis       Date:  2021-07-15       Impact factor: 5.226

9.  Lyme disease: clinical diagnosis and treatment.

Authors:  T F Hatchette; I Davis; B L Johnston
Journal:  Can Commun Dis Rep       Date:  2014-05-29

10.  Lyme borreliosis and skin.

Authors:  Biju Vasudevan; Manas Chatterjee
Journal:  Indian J Dermatol       Date:  2013-05       Impact factor: 1.494

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.